12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Company News  |  Deals

Illumina, Roche deal

Illumina and Roche each filed a definitive proxy statement with the SEC and sent letters to the biotech's shareholders regarding the pharma's unsolicited tender offer to acquire Illumina for $44.50 per...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >